Abstract
2-Hydroxy-4-methoxybenzophenone (HMB) is a common ingredient in personal care products and used as an UV stabilizer. In these studies, disposition and metabolism of [14C]HMB in rats and mice was assessed following single gavage administration (10, 100, or 500 mg/kg), single IV administration (10 mg/kg), or dermal application (0.1, 1, 10, or 15 mg/kg).
Following gavage administration, [14C]HMB was well absorbed and excreted mainly in urine (39–57%) and feces (24–42%) with no apparent difference between doses, species or sexes. Distribution of HMB in tissues was minimal in rats (0.36%) and mice (<0.55%).
Distribution of HMB following dermal application was comparable to that following gavage administration; no differences between doses, sexes, or species were observed but absorption varied between dose vehicles. Light paraffin oil had the highest absorption and excretion (98% of the HMB dose absorbed).
In rats, HMB slowly appeared in the systemic circulation (Tmax ∼2–6 h) and had poor bioavailability (F%<1).
Urine metabolites for both species and all routes included HMB, HMB-glucuronide, 2,4-dihydroxybenzophenone (DHB), DHB-glucuronide, and DHB-sulfates, and novel minor dihydroxy metabolites including 2,5-dihydroxy-4-methoxybenzophenone.
In vitro hepatic metabolism in mice differed from human and in vivo metabolism especially for phase II conjugates.
Acknowledgements
Authors would like to thank Mr. Bradley J. Collins and Dr. Madelyn C. Huang for their review of this manuscript.
Disclosure statement
No potential conflict of interest was reported by the authors.
Data availability statement
Please see below for raw data link for the reviewers; https://doi.org/10.22427/NTP-DATA-002-01338-0023-0000-2